Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC18A1 | P54219 | 1/20 | 0.33 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922250 | 0.81 | BRD4 (0.54) | BRD4BRD9BRD7RXRATDP1 | |
| SCHEMBL9922244 | 0.78 | BRD4 (0.51) | BRD4BRD9BRD7RXRATDP1 | |
| SCHEMBL9922249 | 0.76 | BRD4 (0.49) | BRD4BRD9BRD7METRXRA | |
| SCHEMBL9922247 | 0.75 | BRD4 (0.46) | BRD4BRD9BRD7RXRATDP1 | |
| SCHEMBL22094614 | 0.75 | ALDH1A1 (0.65) | BRD4ALDH1A1IMPDH2KDM4EBRD9 | |
| SCHEMBL31309018 | 0.75 | ALDH1A1 (0.65) | BRD4ALDH1A1IMPDH2KDM4EBRD9 | |
| SCHEMBL12160638 | 0.75 | BRD4 (0.48) | BRD4RXRATDP1 | |
| SCHEMBL9922698 | 0.75 | BRD4 (0.48) | BRD4ALDH1A1IMPDH2KDM4E | |
| SCHEMBL9922697 | 0.74 | BRD4 (0.48) | BRD4KDM4EL3MBTL1 | |
| SCHEMBL12160634 | 0.74 | BRD4 (0.47) | BRD4ALDH1A1KDM4EBRD9BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | BRD4 3757/4885ALDH1A1 1520/4885IMPDH2 1148/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | BRD4 3064/4885ALDH1A1 1379/4885IMPDH2 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.